{"filing":{"accession_number":"0001493152-26-044078","cik":"0001828673","ticker":"HCWB","company_name":"HCW Biologics Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-23","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226044078/form8-k.htm"},"events":[{"id":34766,"run_id":32012,"accession_number":"0001493152-26-044078","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"HCW Biologics entered into a Securities Purchase Agreement on September 23, 2026, to issue 903,614 pre-funded warrant units at $1.6599 per unit for approximately $1.5 million in gross proceeds. The filing explicitly discloses this as an unregistered private placement under Section 4(a)(2) and Regulation D (Item 3.02), with the investor receiving pre-funded warrants exercisable immediately at $0.0001 per share and common warrants (subject to stockholder approval) exercisable at $1.66 per share. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital for working capital and clinical development activities.","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":38607,"accession_number":"0001493152-26-044078","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"HCW Biologics entered into a Securities Purchase Agreement on September 23, 2026, to issue 903,614 pre-funded warrant units at $1.6599 per unit for approximately $1.5 million in gross proceeds. The filing explicitly discloses this as an unregistered private placement under Section 4(a)(2) and Regulation D (Item 3.02), with the investor receiving pre-funded warrants exercisable immediately at $0.0001 per share and common warrants (subject to stockholder approval) exercisable at $1.66 per share. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital for working capital and clinical development activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:06:45.945226+00:00","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-09-24"}]}